The authors reply

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 776-

  Ledgerwood, Julie E ^a   Sullivan, Nancy J ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAD3 ANTIBODY; CHIMPANZEE ADENOVIRUS TYPE 3 VECTORED EBOLAVIRUS VACCINE; EBOLA VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AFRICA; ANTIBODY TITER; CARIBBEAN; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; IMMUNOGENICITY; INDIA; LETTER; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SAFETY; WESTERN HEMISPHERE; ANIMAL; EBOLA HEMORRHAGIC FEVER; GENE VECTOR; IMMUNOLOGY; PAN TROGLODYTES; SIMIAN VIRUS;

ADENOVIRUSES, SIMIAN; ANIMALS; EBOLA VACCINES; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; PAN TROGLODYTES;

EID: 84939809433     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1505499     Document Type: Letter

References (4)

1. Ogwang C, Kimani D, Edwards NJ, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 2015; 7: 286re5.
2. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29: 304-13.
3. Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 2013; 190: 2720-35.
4. Rampling T, Ewer K, Bowyer G, et al. A monovalent chimpanzee adenovirus Ebola vaccine - preliminary report. N Engl J Med 2015. DOI: 10.1056/NEJMoa1411627.